New approaches in primary central nervous system lymphoma

Area of Science:

• Neuro-oncology
• Hematology
• Clinical Medicine

Background:

• Primary central nervous system lymphoma (PCNSL) historically has a poor prognosis compared to other aggressive non-Hodgkin's lymphomas (NHLs).
• Recent clinical experience indicates improved outcomes with modern treatment strategies.
• Long-term progression-free survival (PFS) is achievable in a significant proportion of PCNSL patients.

Purpose of the Study:

• To review current diagnostic and management principles for PCNSL.
• To update knowledge on the molecular pathogenesis of PCNSL.
• To provide a basis for developing more effective therapies for this aggressive NHL subtype.

Main Methods:

• Review of clinical experience and recent literature on PCNSL treatment.
• Focus on dose-intensive consolidation chemotherapy and avoidance of whole brain radiotherapy.
• Evaluation of immunochemotherapy induction regimens followed by consolidation.

Main Results:

• Dose-intensive consolidation chemotherapy, avoiding whole brain radiotherapy, enhances PFS in PCNSL patients.
• An induction regimen of methotrexate, temozolomide, and rituximab followed by etoposide plus high-dose cytarabine (EA) consolidation shows efficacy.
• Other high-dose chemotherapy regimens also demonstrate effectiveness.

Conclusions:

• Modern treatment approaches, particularly dose-intensive chemotherapy, are improving outcomes for PCNSL.
• Further research into molecular pathogenesis is crucial for advancing therapies.
• Optimizing treatment strategies can lead to better long-term PFS for PCNSL patients.